



PATENT

APR 05 2002

TECH CENTER 1600/2900

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Albert P. TSENG, et al.

Examiner: Unassigned

Serial No.: 9/831,744

Art Unit: Unassigned

Filed: May 11, 2001

Docket: 13030

For: PHOSPHOLIPASE INHIBITORS
FOR THE TREATMENT OF CANCER

Dated: March 13, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. PCT WO 98/10776, published March 19, 1998;
2. PCT WO 91/09603, published July 11, 1991;
3. United States Patent No. 5,663,059, dated September 2, 1997;
4. United States Patent No. 5,811,520, dated September 22, 1998; and
5. PCT WO 97/35588, published October 2, 1997.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on March 13, 2002.
Dated: March 13, 2002

Michelle Mustafa

The references were cited in a Search Report received from the PCT International Patent Office dated January 5, 2000. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Frank S. DiGilio
Registration No. 31,346

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

FSD:ahs

1600

JCA rec'd FEB 22 2002


P C

Docket No.
13030

APR 5 2002

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

In Re Application Of: Albert P. TSENG, et al.

P#
1600Serial No.
09/831,744Filing Date
May 11, 2001Examiner
UnassignedGroup A/B Unit
Unassigned

Title: PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER

RECEIVED

Address to:
Assistant Commissioner for Patents
 Washington, D.C. 20231

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
 2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- a certification as specified in 37 CFR 1.97(e);

OR

- the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.98(d))
 P E

Docket No.

13030

APR 05 2002

RECEIVED
ENTER 160100
2002

In Re Application Of: Albert P. TSENG, et al.



Serial No. 09/831,744	Filing Date May 11, 2001	Examiner Unassigned	Group Art Unit Unassigned
--------------------------	-----------------------------	------------------------	------------------------------

Title: PHOSPHOLIPASE INHIBITORS FOR THE TREATMENT OF CANCER

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No.

) on _____
(Date)

Signature

[Signature]
Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on March 13, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

[Signature]
Signature of Person Mailing Correspondence

Michelle Mustafa

[Signature]
Typed or Printed Name of Person Mailing Correspondence

Dated: March 13, 2002

[Signature]
Signature
Frank S. DiGiglio, Reg. No. 31,346
SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, NY 11530
(516) 742-4343

FSD:ahs

CC: